Overview

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Status:
Not yet recruiting

Trial end date:
2025-02-28

Target enrollment:

Participant gender:

Summary

This phase I/II trial compares the effect of adding selinexor to the usual chemotherapy treatment (temozolomide) to temozolomide alone for the treatment of patients with glioblastoma (a type of brain tumor) that has come back (recurrent). Selinexor is not in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving selinexor with temozolomide may shrink or stabilize the tumor in patients with brain cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Temozolomide